The European Hematology Association 2026 Congress (EHA 2026)

Stockholm, Sweden 11 June 2026 - 14 June 2026

Novel SYK inhibitor elicits durable Hb response in autoimmune haemolytic anaemia

The highly selective oral spleen tyrosine kinase (SYK) inhibitor sovleplenib has demonstrated significant clinical benefit in patients with warm autoimmune haemolytic anaemia (wAIHA), with durable haemoglobin (Hb) response and a favourable safety profile, as shown in the phase III ESLIM-02 trial.

Novel SYK inhibitor elicits durable Hb response in autoimmune haemolytic anaemia

4 hours ago

1-year fixed-duration venetoclax-obinutuzumab goes a long way in CLL

a day ago by

The final results of the CLL14 trial validate the long-term efficacy of 1-year fixed-duration venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukaemia (CLL) and co-existing conditions.

1-year fixed-duration venetoclax-obinutuzumab goes a long way in CLL

a day ago

MonumenTAL-3 supports talquetamab–daratumumab ± pomalidomide for RRMM

08 Jul 2026 by

In the phase III MonumenTAL-3 trial, talquetamab plus daratumumab (Tal-D), with or without pomalidomide, shows substantial efficacy in the treatment of relapsed/refractory multiple myeloma (RRMM), compared with daratumumab, pomalidomide, and dexamethasone (DPd).

MonumenTAL-3 supports talquetamab–daratumumab ± pomalidomide for RRMM

08 Jul 2026

Efgartigimod improves platelet response in primary ITP

07 Jul 2026 by

The use of efgartigimod in adult patients with primary immune thrombocytopenia (ITP) results in higher platelet response with no increase in serious adverse events (AEs), reports a meta-analysis of phase III randomized controlled trials (RCTs).

Efgartigimod improves platelet response in primary ITP

07 Jul 2026

Pooled analysis validates iptacopan safety for PNH

06 Jul 2026 by

A pooled analysis presented at EHA 2026 demonstrates the long-term safety of the oral proximal complement inhibitor iptacopan in the treatment of paroxysmal nocturnal haemoglobinuria (PNH).

Pooled analysis validates iptacopan safety for PNH

06 Jul 2026

Upfront immunosuppression regimen improves survival in acquired haemophilia A

05 Jul 2026 by

In the first-line treatment of acquired haemophilia A (AHA), the use of an intravenous (IV) pulse-dose immunosuppression regimen that combines cyclophosphamide, dexamethasone, and rituximab appears to result in faster remission and improved survival compared with traditional oral sequential prednisone-based regimens, according to a study.

Upfront immunosuppression regimen improves survival in acquired haemophilia A

05 Jul 2026

Mitapivat RISEs UP as a potential Tx alternative for sickle cell disease

03 Jul 2026 by

In the phase III RISE UP trial, mitapivat—approved for pyruvate kinase (PK) deficiency and thalassemia—shows a strong antihaemolytic effect in individuals with sickle cell disease (SCD).

Mitapivat RISEs UP as a potential Tx alternative for sickle cell disease

03 Jul 2026

Two chemo cycles sufficient prior to HSCT in MRD-negative acute myeloid leukaemia

02 Jul 2026 by

For children and young adults with acute myeloid leukaemia (AML) and measurable residual disease (MRD) negativity, proceeding to allogeneic hematopoietic stem cell transplant (HSCT) after two rounds of chemotherapy is as effective as completing a third cycle prior to HSCT, yielding similar transplant outcomes, according to a multicentre retrospective study.

Two chemo cycles sufficient prior to HSCT in MRD-negative acute myeloid leukaemia

02 Jul 2026

Chemo-free regimen a potential new standard of care in paediatric APL

01 Jul 2026 by

In children with newly diagnosed acute promyelocytic leukaemia (APL), the use of a chemotherapy-free treatment protocol is safe and efficacious, according to the early final results of the ICC-APL-02 study.

Chemo-free regimen a potential new standard of care in paediatric APL

01 Jul 2026

Novel factor B inhibitor superior to eculizumab in paroxysmal nocturnal haemoglobinuria

01 Jul 2026 by

Treatment with the factor B inhibitor HSK39297 is more efficacious than eculizumab for the management of paroxysmal nocturnal haemoglobinuria (PNH), with no serious safety concerns, suggests a study presented at EHA 2026.

Novel factor B inhibitor superior to eculizumab in paroxysmal nocturnal haemoglobinuria

01 Jul 2026